U.S. Markets close in 4 hrs 31 mins
  • S&P 500

    4,363.10
    -69.89 (-1.58%)
     
  • Dow 30

    34,070.50
    -514.38 (-1.49%)
     
  • Nasdaq

    14,737.82
    -306.15 (-2.04%)
     
  • Russell 2000

    2,189.48
    -47.39 (-2.12%)
     
  • Crude Oil

    70.91
    -1.06 (-1.47%)
     
  • Gold

    1,765.10
    +13.70 (+0.78%)
     
  • Silver

    22.36
    +0.07 (+0.29%)
     
  • EUR/USD

    1.1740
    +0.0008 (+0.0704%)
     
  • 10-Yr Bond

    1.3280
    -0.0420 (-3.07%)
     
  • Vix

    24.76
    +3.95 (+18.98%)
     
  • GBP/USD

    1.3672
    -0.0065 (-0.4758%)
     
  • USD/JPY

    109.4660
    -0.4290 (-0.3904%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,097.07
    -37.31 (-3.29%)
     
  • FTSE 100

    6,911.38
    -52.26 (-0.75%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

Have $2,000? 2 All-Weather Stocks to Buy This Month

·5 min read
Have $2,000? 2 All-Weather Stocks to Buy This Month
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Two top-notch stocks from very different sectors -- healthcare and e-commerce -- have continued to generate high levels of balance sheet and business growth throughout the pandemic and each has something to offer a well-rounded portfolio. Vertex Pharmaceuticals (NASDAQ: VRTX) is by far one of the most important players in the global multi-billion-dollar cystic fibrosis (CF) drug industry. The company has four approved drugs on the market: Trikafta, Symdeko, Orkambi, and Kalydeco.